Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.
about
Identification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strainsCharacteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, ChinaHIV-1 Genetic Variability and Clinical ImplicationsEffects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations.Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.Subtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirineSubunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase.Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.Molecular mechanism of antagonism between the Y181C and E138K mutations in HIV-1 reverse transcriptaseNew subtypes and genetic recombination in HIV type 1-infecting patients with highly active antiretroviral therapy in Peru (2008-2010)Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir.Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitorsBasis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug ResistanceThe connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Are subtype differences important in HIV drug resistance?Drug resistance in HIV-1.Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication.A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs.M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.Clinical and analytical relevance of NNRTIs minority mutations on viral failure in HIV-1 infected patients.Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
P2860
Q28537991-095DD9C4-DC97-48B7-939E-59C83A2E0D2EQ28539927-3F0BF516-08C4-4ABA-B212-75CAA71A8317Q30352010-1B42008E-1846-472A-B719-6F546991E7C4Q34058254-818596F4-DD73-4FCF-8E74-B4C1F295332FQ34303603-4F1E3873-5327-4020-A3E6-1DAD7C4AADAAQ35363054-61D5AB30-67A6-44C8-8C32-B5E21ACC105BQ35363594-034646A9-EBC2-4710-9C08-71F122B14A77Q35607740-164DE840-BBB0-4118-A074-C56072D3C475Q35689311-E165F388-0F41-4468-AFC9-BADAC197CE66Q36172087-B8641B88-E39B-4A84-9C40-A28CAFE0619BQ36276790-F04E0E78-DEE5-47DF-BB48-227B70D2427AQ36397384-5D59AB6D-897D-49A8-A7A4-2208DCAFE4AEQ36429586-88858FE7-1F0F-4440-9268-A71FE4119FE7Q36603434-4D42344B-EAE9-4FC4-AAC6-A86FC270BCE9Q36969977-F705F858-1D4C-4061-BBF5-BA853797BFD0Q37263541-103E3657-F5CB-4744-A7D4-5520C7B7D3FEQ37263786-0861B5AA-B998-448F-9E12-3D7C2DB7932AQ37288671-8E894DEC-E9B4-4A68-9489-EA93643AF229Q37547275-21816ADC-BBFB-4F75-9768-C1D8ABE8E121Q37633109-4D7C9C48-FCD1-4EC0-A182-FA87A9523B23Q37967710-A960D39F-77CA-4388-98DC-4C031F9278A5Q38060236-AA59CBFB-56C6-403D-98A7-C2C3981D09EBQ39627553-0B6EA963-A525-494E-B78E-87AD3B54BBB2Q41927879-927FD54D-E465-4BAE-96DB-A68BD018D40EQ42254682-D445EEDA-FD93-43EC-AD73-19AC8060C2DCQ52596192-F17CB42C-4BA0-4AEE-95E9-4351D602F6C5
P2860
Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Characterization of the E138K ...... in B and non-B HIV-1 subtypes.
@ast
Characterization of the E138K ...... in B and non-B HIV-1 subtypes.
@en
Characterization of the E138K ...... in B and non-B HIV-1 subtypes.
@nl
type
label
Characterization of the E138K ...... in B and non-B HIV-1 subtypes.
@ast
Characterization of the E138K ...... in B and non-B HIV-1 subtypes.
@en
Characterization of the E138K ...... in B and non-B HIV-1 subtypes.
@nl
prefLabel
Characterization of the E138K ...... in B and non-B HIV-1 subtypes.
@ast
Characterization of the E138K ...... in B and non-B HIV-1 subtypes.
@en
Characterization of the E138K ...... in B and non-B HIV-1 subtypes.
@nl
P2093
P2860
P356
P1476
Characterization of the E138K ...... in B and non-B HIV-1 subtypes.
@en
P2093
Bluma G Brenner
Cecile L Tremblay
Daniela Moisi
Eugene L Asahchop
Mark A Wainberg
Maureen Oliveira
Thomas d'Aquin Toni
P2860
P304
P356
10.1128/AAC.01192-10
P407
P577
2010-12-06T00:00:00Z